Insmed Incorporated
NASDAQ•INSM
CEO: Mr. William H. Lewis J.D., M.B.A.
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Listing Date: 2000-06-01
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Contact Information
Market Cap
$21.21B
P/E (TTM)
-17.8
54.5
Dividend Yield
--
52W High
$212.75
52W Low
$90.39
52W Range
Rank71Top 99.6%
1.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data